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142 The Journal of Thoracic and Cardbjective: Lung retransplantation is a controversial practice due to increased mor-
idity and mortality and the scarcity of available donor organs. Living donor lobar
ung transplantation increases the number of available donor organs and facilitates
more organized procedure than traditional cadaveric donation for this complex
eoperation. The purpose of this study was to evaluate our experience with pediatric
ung retransplantation and to compare the outcomes of living donor lobar lung
ransplantation with cadaveric donation.
ethods: Retrospective review of a prospectively collected database identified 39
hildren who underwent lung retransplantation from 1991 to 2004. Retransplanta-
ion was performed with living donor lobar lung transplantation in 13 patients and
adaveric donation in 26 patients. Short- and long-term outcomes were compared
etween the 2 groups.
esults: Perioperative mortality was 1/13 (7.7%) in the patients who had living donor
obar lung transplantation versus 11/26 (42.3%) in the cadaveric donation group
P  .03). Five-year survival for living donor lobar lung transplantation and
adaveric donation was 40.4% and 29.7%, respectively (P  .27). Both groups had
significant improvement in their forced expiratory volume in 1 second 6 months
fter retransplantation (P  .001). Multivariate analysis identified the use of
adaveric donation (relative risk  6.16, P  .001) and early graft dysfunction
relative risk  6.19, P  .001) as the major independent predictors of decreased
urvival following retransplantation.
onclusions: Living donor lobar lung transplantation reduces perioperative mortal-
ty and is an independent predictor of improved survival following pediatric lung
etransplantation. This strategy offers significant benefit for this high-risk group and
reserves the limited supply of donor lungs for other children at risk of dying while
aiting for lung transplantation.
ung retransplantation has been used at our center for highly selected patients
with bronchiolitis obliterans syndrome (BOS) and acute graft dysfunction.
Acute graft dysfunction is the leading cause of perioperative mortality and
ccounts for over 40% of early deaths.1 BOS develops in 45% of pediatric lu
ecipients within 5 years and is the most common cause of late graft failure and
eath.1 The only treatment for many of these patients is retransplantation. It is a
iovascular Surgery ● May 2006
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TXontroversial practice because of higher morbidity and
ower survival compared with primary transplantation.2-5 In
ddition, the donor lung shortage raises ethical questions
bout the use of the precious cadaveric lung resource for
etransplantation while other children die waiting for their
rst lung transplant.
Living donor lobar lung transplantation (LDLT) was
eveloped in 1993 in response to the mismatch between
upply and demand for those individuals awaiting lung
ransplantation.6 As more patients are being listed for l
ransplantation, the median waiting time for cadaveric or-
ans has doubled and more patients die on the waiting7
ur center has used LDLT for retransplantation since 1994. It
ugments the donor pool for retransplantation and preserves
he cadaveric donor pool. In addition, LDLT facilitates a
ore elective and organized operation and reduces the isch-
mic time in this high-risk group. The purpose of this study
as to evaluate our experience with pediatric lung retrans-
lantation at a single center and compare the outcomes
sing LDLT and traditional cadaveric donors (CDs).
aterials and Methods
atients
rom November 1991 through September 2004, 39 lung retrans-
lantations were performed at St Louis Children’s Hospital, Wash-
ngton University School of Medicine. Thirty-eight of the 39 initial
ung transplantations were performed using CDs. Thirteen of the
etransplantations were performed using LDLT and 26 with CDs.
Abbreviations and Acronyms
BOS  bronchiolitis obliterans syndrome
CD  cadaveric donor
LDLT living donor lobar lung transplantation
ABLE 1. Baseline characteristics
LDLT (n  13)
ge (y) 17.3  3.3
ender (female) 7 (53.8%)
rimary diagnosis
Cystic fibrosis 11 (84.6%)
Pulmonary vascular disease 2 (15.4%)
Other pulmonary disease 0
ndication for retransplantation
Bronchiolitis obliterans 11 (84.6%)
Primary graft failure 2 (15.4%)
xygen requirement
None 0
O2 support 10 (76.9%)
Ventilated 3 (23.1%)
ime from first transplant (d) 1046  849 944 (IQR: 3QR, Intraquartile range.
The Journal of Thoracic.
he donor lobectomies for LDLT were performed by 2 separate
perating teams at Barnes-Jewish Hospital and utilized the right
nd left lower lobes from 2 different donors. Our strategy for
DLT selection and operative technique were recently review8
retransplant Diagnosis
he characteristics of patients undergoing lung retransplantation
re listed in Table 1. The oxygen requirements were similar in
roups (P  .2) with 20% to 40% of the patients requiring
echanical ventilation prior to retransplantation. The 2 indications
or retransplantation were BOS (80%) and primary graft dysfunc-
ion (20%). BOS was the most common indication and the timing
f retransplantation depended on the severity of the clinical picture
nd the judgment of the pulmonary transplant team. These patients
ere highly motivated, adherent to their treatment protocols, and
ad good social support systems. Primary graft dysfunction was
reated with standard ventilatory support, intensive hemodynamic
upport, and nitric oxide when the pulmonary artery pressures or
ulmonary vascular resistance were elevated. Only those patients
emonstrating a progressive deterioration were considered for
etransplantation. In addition, these patients had to be free of sepsis
nd without any evidence of other organ failure.
ransplantation Technique
ll retransplantation procedures were performed using cardiopul-
onary bypass and 38 of 39 were bilateral. Only 1 unilateral retrans-
lantation was performed using a CD for a patient with acute graft
ailure. During the 13-year series, there was no difference in the
istribution of LDLT and CD retransplantation. Bilateral antero-
ateral transsternal (clamshell) thoracotomies were performed for
he 38 sequential lung retransplantations, and bronchial anastomo-
es were wrapped with donor and recipient peribronchial tissue.
he bronchial anastomosis was performed using monofilament
bsorbable sutures in a running fashion for the membranous por-
ion and in an interrupted fashion for the cartilaginous portion. A
roviac catheter (Bard Systems Inc, Salt Lake City, Utah) was
laced to maintain chronic vascular access. Vascular anastomoses
CD (n  26) P value
13.2  5.6 .020
11 (42.6%) .520
13 (50.0%) .056
5 (19.2%)
8 (30.8%)
.694
20 (76.9%)
6 (23.1%)
.204
3 (11.5%)
13 (50.0%)
10 (38.5%)
85) 1318  1256 747 (IQR: 251-2409) .80041-16and Cardiovascular Surgery ● Volume 131, Number 5 1143
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1
TXere performed with running nonabsorbable suture. After the first
raft is implanted, we have the perfusionist leave blood in the heart
rom the cardiopulmonary bypass circuit so that there is eje
nto the pulmonary vasculature to a pulmonary artery pressure of
round 20 mm Hg systolic. The lung is ventilated at pressures of
0/5 cm H2O until the second bronchus is opened and then
entilation is discontinued.
mmunosuppression and Surveillance
ll patients were treated with triple immunosuppressive therapy
onsisting of cyclosporine or tacrolimus, azathioprine or myco-
henolate mofetil, and prednisone. Patients received standardized
rophylaxis against Candida species, Pneumocystis carinii, and,
or patients at risk, cytomegalovirus. All patients were followed up
ontinuously at our center. Surveillance bronchoscopy with trans-
ronchial biopsies were performed at regular intervals to rule out
cute rejection. Biopsies were unilateral in cadaveric donors and
ilateral in living lobar donors because the lower lobes came from
different donors. Acute rejection was graded according to the
lassification of the International Society for Heart and Lung
ransplantation.9 Acute rejection was treated with bolus doses
ethylprednisolone (10 mg/kg) daily for 3 days. Refractory acute
ejection was treated with a 10-day course of antithymocyte glob-
lin followed by a change in maintenance immunosuppression.
ulmonary function tests were also performed at regular intervals.
hildren under the age of 5 years who were unable to cooperate for
ABLE 2. Perioperative and surgical morbidity
LDLT (n  13) CD (n  26) P value
ype of transplant
performed
Bilateral 0 25 (96.2%)
Single 0 1 (3.8%)
Bilateral lobar (living) 13 (100%) 0
schemic time (minutes)
First lung 88.6  23.1 274.8  63.1 .001
Second lung 102.3  28.0 324.1  70.6 .001
ardiopulmonary
bypass time
(minutes)
250.2  49.7 191.3  45.6 .001
equired reexploration 6 (46.2%) 12 (46.2%) .999
equired ECMO support
posttransplant
1 (7.7%) 4 (15.4%) .648
arly graft dysfunction 5 (38.5%) 13 (50.0%) .734
cute renal failure 2 (15.4%) 9 (34.6%) .276
equired reintubation 6 (46.2%) 16 (61.5%) .497
ength of mechanical
ventilation (days)
6 (IQR: 4-13) 8 (IQR: 3-27) .520
ength of stay in ICU
(days)
8 (IQR: 7-15) 10 (IQR: 5-29) .643
ength of stay in
hospital (days)
29 (IQR: 14-32) 18 (IQR: 13-49) .881
ospital mortality 1 (7.7%) 11 (42.3%) .034
CMO, Extracorporeal membrane oxygenation; ICU, intensive care unit;
QR, intraquartile ranges.tandard pulmonary function tests were evaluated with infant pulmo- n
144 The Journal of Thoracic and Cardiovascular Surgery ● Maary function tests.10 The majority of patients received a porta
andheld spirometer to measure pulmonary function on a daily
asis at home. BOS was defined according to standard spirometric
riteria or by lung biopsy.10
tatistical Analysis
ormally distributed continuous data are expressed as mean 
tandard deviation. Medians with intraquartile ranges are used
hen continuous data is skewed. Categorical data are expressed as
ounts and proportions. Comparisons were performed with paired
nd independent, 2-tailed t tests for means of normally distributed
ontinuous variables, and the Wilcoxon rank-sum test for skewed
ata. Chi-square or Fisher exact test were used to analyze differ-
nces in proportions among the categorical data. Kaplan-Meier
stimate was used to estimate survival and freedom from BOS.
urvival and BOS-free survival comparison between groups of
atients was completed using the Mantel-Haenszel log-rank test.
ox multivariate proportional hazards regression model was used
o identify independent risk factors for death in the studied patient
opulation including the variables of age, time from primary
ransplantation to retransplantation, type of allograft utilized, need
or mechanical ventilation at the time of retransplantation, primary
nd-stage lung disease, indication for retransplantation, mean al-
ograft ischemic time, and the occurrence of early graft dysfunc-
ion. All data analysis was performed using SPSS (SPSS 11.0 for
indows: SPSS Inc, Chicago, Ill). The Washington University
edical Center Human Studies Committee granted approval for
his research.
esults
erioperative
he length of cardiopulmonary bypass and the ischemic times
re listed in Table 2. The ischemic times were dramati
horter in the LDLT group. Post-retransplantation hospital-
zation variables including days mechanically ventilated,
ength of stay in the intensive care unit, and hospital length
f stay were compared between the 2 groups. There were no
ignificant differences in these post-retransplantation vari-
bles (P  .52).
urgical Morbidity
urgical morbidity was relatively high in both groups but
ABLE 3. Late morbidity
LDLT (n  13) CD (n  26) P value
reated for airway
complication
1 (7.7%) 3 (11.5%) .999
ocal cord paralysis 1 (7.7%) 1 (3.8%) .999
hronic renal insufficiency 6 (46.2%) 9 (34.6%) .508
iaphragm dysfunction 4 (30.8%) 8 (30.8%) .999
iagnosed with PTLD 1 (7.7%) 1 (3.8%) .999
cute rejection episodes 1.4  2.0 0.9  1.5 .347
o. of biopsies performed 7.6  5.7 6.9  5.2 .404
TLD, Posttransplant lymphoproliferative disorder.ot statistically different (Table 2). We have defined early
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TXraft dysfunction as requiring mechanical ventilation for
ore than 7 days or a chest radiograph with a characteristic
iffuse bilateral infiltrate.
ate Outcomes
ate outcomes are reported in Table 3 and were not s
cantly different between the groups. Acute rejection is
eported as the number of episodes per patient along with
he number of biopsies performed.
Freedom from BOS at 5 years was 90% for LDLT and
7.2% for CD (P  .41; Figure 1). Although the LDL
roup had half the incidence of BOS at 5 years, the 2 groups
ere not significantly different due to the small sample size
nd possible type II error. Pulmonary function was com-
ared between the two groups for those patients who sur-
ived 6 months (Figure 2). Both groups had a signifi
mprovement in their forced expiratory volume in 1 second
months after retransplantation (P  .001) but the degree
igure 1. Freedom from BOS. Kaplan-Meier analysis comparing
reedom from BOS between LDLT and CD lung retransplantation.
igure 2. Pulmonary function testing. Improvement in percent
redicted forced expiratory volume in 1 second 6 months afterwetransplantation.
The Journal of Thoracic-
t
f improvement was higher in the CD group receiving
ilateral complete lung transplants.
ortality
he hospital mortality was 7.7% (1/13) for LDLT and
2.3% (11/26) for CD (P  .03). The 1 death in the LDLT
roup was secondary to infection in a 14-year-old boy who
as initially transplanted for cystic fibrosis. He was the only
of 3 ventilated patients in the LDLT group to die perio-
eratively. The causes of death for the CD group were graft
ailure/respiratory failure (n  6), infection (n  4), and
ultisystem organ failure (n  1). Four of 10 patients who
ere mechanically ventilated prior to retransplantation in
he CD group had perioperative deaths. The Kaplan-Meier
-year survival was 40.4% for LDLT and 29.7% for CD
P  .27; Figure 3).
ABLE 4. Results of multivariate analysis of prognostic
actors influencing survival for patients following retrans-
lantation
ariable n
Relative
risk
95%
confidence
interval
P
value
ype of allograft utilized
Living lobar 13 1.000 — —
Cadaveric 26 6.162 2.050-18.519 .001
arly graft dysfunction
No 21 1.000 — —
Yes 18 6.192 2.143-17.888 .001
ge at transplantation (y) 39 1.295 1.123-1.492 .001
ime to retransplantation (y) 39 0.702 0.559-0.881 .001
equiring mechanical ventilation at the time of retransplantation, primary
nd-stage lung disease diagnosis, indication for retransplantation, and
ean allograft ischemic time were covariates entered into the model but
igure 3. Survival following pediatric lung retransplantation.
aplan-Meier analysis of survival comparing LDLT with CD lung
etransplantation.ere not found to be significant predictors.
and Cardiovascular Surgery ● Volume 131, Number 5 1145
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1
TXrognostic Factors Influencing Survival
Cox proportional hazards model was used to identify inde-
endent prognostic factors influencing survival (Table 
he two major predictors of decreased survival were use of
adaveric donors and the presence of early graft dysfunc-
ion. A shorter time to retransplantation and older age of the
ecipient were minor prognostic factors.
unctional Status
urrent follow-up data on 13 surviving patients were ob-
ained from clinic records. Ten children are fully active and
ble to participate with school and normal activities of daily
iving. Three children are limited in their activities due to
omplications resulting from chronic renal insufficiency.
hey have required dialysis and are being evaluated for
ossible renal transplantation.
iscussion
ung retransplantation poses an ethical dilemma between
aximizing the distribution of the scarce donor lung supply
o the greatest number of patients versus optimizing the
utcome of individual patients. It is even more difficult
hen the patients are children and the mortality on the
aiting list approaches 30%. The literature provides little
ata on pediatric lung retransplantation because the majority
f reports deal exclusively with adults.3,11 This provided th
ncentive for our group to investigate the use of LDLT in
etransplantation.
LDLT dramatically reduced ischemic time (Table 2) 
ause there was no extended travel time associated with
rocurement from distant centers. In addition, the donor
obectomies were carefully coordinated with the recipient
etransplantation, facilitating a more elective and organized
peration. One may anticipate that the dramatic reduction in
schemic time due to LDLT would decrease the incidence of
arly graft dysfunction but this was not observed in our
eries (Table 2). One explanation for this is due to
iberal definition of early graft failure, which includes me-
hanical ventilation for 7 days or diffuse bilateral infiltrates.
owever, no patients in the LDLT group died from early
raft dysfunction, which was the most common cause of hos-
ital mortality in the CD group (6/11 deaths). Only 1 patient
n the LDLT retransplantation group died perioperatively,
econdary to infection. Our 8% perioperative mortality with
DLT retransplantation compares favorably to the 12%
erioperative mortality following primary LDLT transplan-
ation reported by Starnes and colleagues.12 This is con-
rasted by the 42% hospital mortality in the CD retransplan-
ation group. More than one third of these patients required
echanical ventilation prior to retransplantation and 50%
uffered early graft dysfunction. The increased periopera-
ive mortality in the CD retransplantation group is similar
o recent reports and reflects the complexity of the proce- h
146 The Journal of Thoracic and Cardiovascular Surgery ● Ma-
r
ure and the poor preoperative functional status of these
hildren.3-5,11
The 5-year survival for the LDLT and CD groups was
0.4% and 29.7%, respectively (P  .27; Figure 3). Th
mprovement in survival for the LDLT group was not sta-
istically significant because the sample sizes were small
nd there may be a type II error (the chance you can miss an
ffect even though one exits). The smaller the sample, the
ore likely you are to commit a type II error, because the
onfidence interval is wider and is therefore more likely to
verlap zero. However, our 5-year survival of 40% for the
DLT retransplants is similar to the 45% 5-year survival of
rimary LDLT reported by Starnes and colleagues.12 Im-
ortantly, their group has published that intubated patients
odds ratio  3) and patients undergoing retransplantation
re at significantly high risk because of poorer outcomes.
lthough one would anticipate that patients requiring me-
hanical ventilation prior to retransplantation would be at
igher risk, univariate and multivariate analysis of this
eries did not demonstrate mechanical ventilation to be an
ndependent predictor of mortality.
The data presented in this series demonstrates that LDLT
ffers advantages over cadaveric donation and may be the
referred method of retransplantation for this high-risk group.
n addition, multivariate analysis demonstrated that LDLT
educed the risk of death following retransplantation by a
actor of 6 (Table 4). BOS is an important determina
urvival and quality of life following lung transplantation.
nfortunately, children may be more susceptible to BOS
ith incidence rates from 45% to 75% within 5 year1,13
DLT has been reported to reduce the incidence of BOS in
ediatric patients.14,15 The 5-year freedom from BOS f-
owing LDLT retransplantation in this series was 90% with
nfection being the most common cause of late death. The
ncidence of BOS between LDLT and CD was not statisti-
ally significant but the differences may become significant
ith longer follow-up (Figure 1). One may speculate 
he increased severity of reperfusion injury in the CD group
nfluenced the trend of developing BOS. As stated previ-
usly, early graft dysfunction was not the cause of mortality
or any patient in the LDLT group but resulted in the death
f 6/11 patients in the CD group. Pulmonary function im-
roved dramatically in both groups (Figure 2). In contra
revious reports, our data demonstrated a larger improve-
ent for the CD group receiving complete bilateral lung
ransplants.15 Importantly, the functional status of patie
urviving retransplantation was excellent: 77% were fully
ctive and 23% were partially limited.
LDLT is an enormous undertaking with physical and
sychological repercussions. It requires a dedicated staff of
ung transplant coordinators, social workers, pulmonolo-
ists, thoracic surgeons, and a large commitment from the
ospital. On average, 5 individuals are screened as potential
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Kozower et al Cardiothoracic Transplantationobar donors to come up with the 2 that will be satisfactory.
well-trained team of transplant coordinators and social
orkers are crucial to facilitate the screening process, help
ith travel plans and housing, and coordinate reimburse-
ent issues. Our criteria for living lobar lung donation were
eviewed previously.8 Every effort is made to keep 
valuation team separate from the transplanting team for
thical purposes. An extensive discussion describing the
onor lobectomy procedure, the potential operative risks to
he donor, and the uncertain outcome for the recipient was
onducted with each potential donor. The entire evaluation
as completely closed to other family members and physi-
ians and if a patient wanted to withdraw, the reason re-
ained anonymous. Although we have experienced no do-
or mortality with 62 donor lobectomies, more than half of
onors had postoperative complications and this needs to be
actored into the decision when LDLT is being conside8
In conclusion, lung retransplantation in children can be
erformed successfully but has increased morbidity and mor-
ality over primary transplantation. Selecting patients for
etransplantation is an extremely difficult process when so
uch has been invested by the patient, their family, and the
ransplant team. Patient selection needs to remain strict
ecause of the increased risk involved and the scarcity of
onor lungs. This series demonstrates that LDLT may be the
rocedure of choice for retransplantation. It facilitates an
rganized operation, dramatically reduces ischemic time
nd hospital mortality, and preserves the pool of cadaveric
onor lungs for other patients on the waiting list. LDLT is
n independent predictor of improved survival following
etransplantation and with longer follow up it may demon-
trate a reduction in BOS and improved 5-year survival.
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